Want to see SG:BSL full AI Analyst Report?
BSL Stock Chart & Stats
S$1.02
>-S$0.01(-0.60%)
At close: 4:00 PM EST
S$1.02
>-S$0.01(-0.60%)
Day’s Range― - ―
52-Week RangeS$0.87 - S$1.08
Previous CloseN/A
Volume814.20K
Average Volume (3M)1.13M
Market Cap
S$1.65B
Enterprise ValueS$1.46K
Total Cash (Recent Filing)S$262.30M
Total Debt (Recent Filing)S$34.18M
Price to Earnings (P/E)23.9
Beta0.32
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.43%
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,884,544,900
10 Day Avg. Volume1,100,720
30 Day Avg. Volume1,133,593
Financial Highlights & Ratios
PEG Ratio1.95
Price to Book (P/B)1.78
Price to Sales (P/S)2.47
P/FCF Ratio19.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
S$1.02Price Target Upside0.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt/equity (~0.08x) materially reduces financial risk and preserves strategic optionality. Over the next 2–6 months this balance-sheet strength supports resilience in downturns, capacity for targeted investment or acquisitions, and maintains liquidity for operations and dividends.
Strong Cash GenerationRobust absolute cash flow (OCF S$109M; FCF S$101M) with FCF close to reported earnings indicates high cash quality. This durable cash generation underpins reinvestment, dividend funding and capital expenditure without reliance on external financing, improving long-term financial flexibility.
Integrated Care NetworkA vertically integrated model (primary care clinics, specialist centres, diagnostics and hospital services) and recurring corporate contracts creates durable referral flows, diversified revenue streams and higher customer retention, supporting more stable utilization and revenue mix over time.
Bears Say
Slowing Revenue GrowthRevenue has decelerated into slight decline, reflecting a weakening top-line trend. Over the coming months, a sustained slowdown constrains margin recovery, reduces economies of scale in clinical operations, and limits capacity to reaccelerate profit growth without structural demand or mix improvements.
Margin CompressionNet margin has fallen sharply from prior peaks, signaling persistent pressure from cost inflation, less favorable case mix or pricing/reimbursement headwinds. Lower sustainable margins impair returns on invested capital and reduce the cushion for reinvestment or dividend maintenance if trends continue.
Lower Cash Conversion Vs RevenueAlthough absolute FCF is strong, OCF relative to revenue (~0.33) is modest, suggesting working-capital inefficiencies or timing differences. Persistently low cash conversion versus revenue can constrain reinvestment efficiency and makes cash buffers more sensitive to revenue volatility over the medium term.
Raffles Medical Group News
BSL FAQ
What was Raffles Medical Group Ltd’s price range in the past 12 months?
Raffles Medical Group Ltd lowest share price was S$0.87 and its highest was S$1.08 in the past 12 months.
What is Raffles Medical Group Ltd’s market cap?
Raffles Medical Group Ltd’s market cap is S$1.65B.
When is Raffles Medical Group Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Raffles Medical Group Ltd’s earnings last quarter?
Currently, no data Available
Is Raffles Medical Group Ltd overvalued?
According to Wall Street analysts Raffles Medical Group Ltd’s price is currently Undervalued.
Does Raffles Medical Group Ltd pay dividends?
Raffles Medical Group Ltd pays a Annually dividend of S$0.03 which represents an annual dividend yield of 3.43%. See more information on Raffles Medical Group Ltd dividends here
What is Raffles Medical Group Ltd’s EPS estimate?
Raffles Medical Group Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Raffles Medical Group Ltd have?
Raffles Medical Group Ltd has 1,884,544,900 shares outstanding.
What happened to Raffles Medical Group Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Raffles Medical Group Ltd?
Currently, no hedge funds are holding shares in SG:BSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Raffles Medical Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
S$1.02 (0.33% Upside)
S$1.02 (0.33% Upside)
Insider Transactions
Bought Shares
Worth S$495.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.09%
12-Months-Change
Fundamentals
Return on Equity
3.43%
Trailing 12-Months
Asset Growth
-8.62%
Trailing 12-Months
Company Description
Raffles Medical Group Ltd
Raffles Medical Group Ltd (RMG), a prominent Singapore-headquartered company, delivers integrated private healthcare services across Singapore, Greater China, Vietnam, Cambodia, and Japan. Its operations are structured into Healthcare Services, Hospital Services, and Investment Holdings segments. The group's flagship institution, Raffles Hospital, functions as a tertiary care facility, offering a broad spectrum of medical services. These include oncology, pediatrics and women's health, traditional Chinese medicine, counseling, dental care, dialysis, diabetes and endocrinology, ENT, ophthalmology, fertility treatments, cardiology, internal medicine, neuroscience, pain management, rehabilitation, orthopedics, dermatological and aesthetic services, general surgery, nuclear medicine, and urology. Beyond the hospital, RMG provides emergency services, family medicine, comprehensive health screening, and a variety of multi-disciplinary specialist clinic services. Additionally, the company engages in the trade of pharmaceutical and nutraceutical products, and diagnostic equipment. It also offers advisory and consultancy services, develops IT solutions, and undertakes research and experimental development in biotechnology, life sciences, and medical science. The company was founded in 1976.
BSL Stock 12 Month Forecast
Average Price Target
S$1.02
▲(0.33% Upside)
Technical Analysis
Thomson Medical Group Ltd.
―
Aoxin Q&M Dental Group Ltd.
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―
Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh
―